Dong-A ST and GC녹십자 Join Hands for Joint Research on New Drug Development for Immune Diseases

Dong-A ST announced on the 6th that it has signed a joint research agreement with GC Green Cross for the development of new drugs for immune diseases.

Exterior view of Dong-A ST headquarters.
[Photo by Dong-A ST]

The two companies plan to jointly select new drug targets that can target chronic inflammatory diseases among immune diseases and conduct joint research to develop treatments using new modalities.

According to the agreement, GC Green Cross will create substances that can act on the selected targets and perform optimization processes to enable delivery to specific organs. Dong-A ST plans to verify the mechanism of action of the substances produced by GC Green Cross at the cellular level and evaluate their efficacy in animal models.

The two companies plan to continue their cooperation in the next stages of development for the substances derived through joint research. The rights to the results obtained will be jointly owned by both companies.

Microorganisms entering our body from outside or damage to our own cells are removed through inflammatory responses. However, if acute inflammation is not properly managed by the immune response, it can lead to chronic inflammation causing tissue damage, which can occur in all organs and tissues of the human body.

Jae-Hong Park, CEO of Dong-A ST, said, "This agreement aims to move away from the standardized forms of joint research in the domestic pharmaceutical and bio industry and to enhance research and development potential by conducting joint research between traditional pharmaceutical companies, leveraging each company's strengths and increasing cooperation in new fields." He added, "We will make every effort to fully utilize the capabilities and resources of both companies to achieve innovative results in the development of new drugs for immune diseases."

Jae-Wook Jung, Head of Research and Development (R&D) at GC Green Cross, said, "We hope that the collaboration between the two companies will bring meaningful changes to patients' lives," and added, "We will continue various forms of cooperation focusing on areas with high unmet medical needs."

This content was produced with the assistance of AI translation services.